Long-Term Effects of Intensive Glucose Lowering on Cardiovascular Outcomes
暂无分享,去创建一个
Michael E. Miller | John B Buse | Faramarz Ismail-Beigi | Michael E Miller | W. Cushman | Y. Rosenberg | J. Bigger | H. Gerstein | R. Byington | F. Ismail-Beigi | S. Genuth | J. Probstfield | R. Grimm | W. Friedewald | J. Buse | D. Goff | H. Ginsberg | David C Goff | Jeffrey L Probstfield | J Thomas Bigger | William T Friedewald | Hertzel C Gerstein | William C Cushman | Richard H Grimm | Saul Genuth | Henry N Ginsberg | Yves D Rosenberg | Robert P Byington | S. Schinner | S. Schinner
[1] S. Kaplan,et al. Comorbidity Affects the Relationship Between Glycemic Control and Cardiovascular Outcomes in Diabetes , 2009, Annals of Internal Medicine.
[2] A. Folsom,et al. Glycemic control and coronary heart disease risk in persons with and without diabetes: the atherosclerosis risk in communities study. , 2005, Archives of internal medicine.
[3] Michael E. Miller,et al. Effects of intensive glucose lowering in type 2 diabetes. , 2008, The New England journal of medicine.
[4] W. Ambrosius,et al. Epidemiologic Relationships Between A1C and All-Cause Mortality During a Median 3.4-Year Follow-up of Glycemic Treatment in the ACCORD Trial , 2010, Diabetes Care.
[5] J. Manson,et al. HbA1c measured in stored erythrocytes and mortality rate among middle-aged and older women , 2008, Diabetologia.
[6] D. Simons-Morton,et al. Effect of Intensive Compared With Standard Glycemia Treatment Strategies on Mortality by Baseline Subgroup Characteristics , 2010, Diabetes Care.
[7] John B Buse,et al. Effects of combination lipid therapy in type 2 diabetes mellitus. , 2010, The New England journal of medicine.
[8] R. Holman,et al. 10-year follow-up of intensive glucose control in type 2 diabetes. , 2008, The New England journal of medicine.
[9] Michael E. Miller,et al. ACTION TO CONTROL CARDIOVASCULAR RISK IN DIABETES STUDY GROUP. EFFECTS OF INTENSIVE GLUCOSE LOWERING IN TYPE 2 DIABETES , 2010 .
[10] Lukasz Januszkiewicz. [The ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus]. , 2010, Kardiologia polska.
[11] Kevin A Peterson,et al. Effects of Intensive Blood-Pressure Control in Type 2 Diabetes Mellitus , 2011 .
[12] H. Gerstein,et al. Glycemia treatment strategies in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. , 2007, The American journal of cardiology.
[13] Mark Woodward,et al. Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies , 2005, BMJ : British Medical Journal.
[14] A. Thanopoulou,et al. Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. , 2010, The New England journal of medicine.
[15] Michael E. Miller,et al. The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: post hoc epidemiological analysis of the ACCORD study , 2010, BMJ : British Medical Journal.
[16] Michael E. Miller,et al. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study , 2010, BMJ : British Medical Journal.